Literature DB >> 16937512

Adverse hepatic reactions associated with calcium carbimide and disulfiram therapy: is there still a role for these drugs?

Carmen Verge1, M Isabel Lucena, Enrique López-Torres, M José Puche-Garcia, Enrique Fraga, Manuel Romero-Gomez, Raúl J Andrade.   

Abstract

Disulfiram and calcium carbimide are two alcohol deterrants widely used in alcoholism treatment, however, there exist great concerns over their safety. Reports on hepatotoxicity, mainly related to disulfiram therapy, have been published. The hepatotoxic potential of calcium carbimide is less well characterized. Here, we describe four cases of liver damage related to this therapeutic group that were submitted to a Registry of hepatotoxicity and point out the limitations that we face when prescribing these compounds. A reassessment of the role of these compounds in the management of alcohol dependence is clearly needed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16937512      PMCID: PMC4087419          DOI: 10.3748/wjg.v12.i31.5078

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  10 in total

1.  Venlafaxine-associated hepatitis.

Authors:  Y Horsmans; M De Clercq; C Sempoux
Journal:  Ann Intern Med       Date:  1999-06-01       Impact factor: 25.391

Review 2.  Criteria of drug-induced liver disorders. Report of an international consensus meeting.

Authors:  C Bénichou
Journal:  J Hepatol       Date:  1990-09       Impact factor: 25.083

3.  Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period.

Authors:  Raúl J Andrade; M Isabel Lucena; M Carmen Fernández; Gloria Pelaez; Ketevan Pachkoria; Elena García-Ruiz; Beatriz García-Muñoz; Rocio González-Grande; Angeles Pizarro; José Antonio Durán; Manuel Jiménez; Luis Rodrigo; Manuel Romero-Gomez; José María Navarro; Ramón Planas; Joan Costa; Africa Borras; Aina Soler; Javier Salmerón; Rafael Martin-Vivaldi
Journal:  Gastroenterology       Date:  2005-08       Impact factor: 22.682

4.  Comparison of two clinical scales for causality assessment in hepatotoxicity.

Authors:  M I Lucena; R Camargo; R J Andrade; C J Perez-Sanchez; F Sanchez De La Cuesta
Journal:  Hepatology       Date:  2001-01       Impact factor: 17.425

Review 5.  Pharmacotherapy, pharmacogenomics, and the future of alcohol dependence treatment, part 1.

Authors:  George A Kenna; John E McGeary; Robert M Swift
Journal:  Am J Health Syst Pharm       Date:  2004-11-01       Impact factor: 2.637

6.  Structural hepatic changes associated with cyanamide treatment: cholangiolar proliferation, fibrosis and cirrhosis.

Authors:  A Moreno; J J Vazquez; L Ruizdel Arbol; F J Guillen; F Colina
Journal:  Liver       Date:  1984-02

7.  Cyanamide hepatotoxicity. Incidence and clinico-pathological features.

Authors:  M Bruguera; A Parés; D Heredia; J Rodés
Journal:  Liver       Date:  1987-08

8.  Clinical characteristics and prognostic markers in disulfiram-induced liver injury.

Authors:  Einar Björnsson; Hans Nordlinder; Rolf Olsson
Journal:  J Hepatol       Date:  2006-02-02       Impact factor: 25.083

Review 9.  Disulfiram-induced hepatitis: case report and review of the literature.

Authors:  N A Mason
Journal:  DICP       Date:  1989-11

Review 10.  A comparative review of the pharmacological and toxicological properties of disulfiram and calcium carbimide.

Authors:  J E Peachey; J F Brien; C A Roach; C W Loomis
Journal:  J Clin Psychopharmacol       Date:  1981-01       Impact factor: 3.153

  10 in total
  1 in total

1.  The effect of curcumin on ethanol induced changes in suprachiasmatic nucleus (SCN) and pineal.

Authors:  Anita Jagota; M Y Reddy
Journal:  Cell Mol Neurobiol       Date:  2007-09-11       Impact factor: 5.046

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.